Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
Allergan Sales, LLC has 6 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 6 examiners and 6 art units, so each action presents a separate examiner and technical setting.
FUBARA, BLESSING M is the busiest examiner, with 1 pending matter. No examiner carries a larger assignment, which makes the docket evenly distributed at the examiner level. Counsel should use centralized review for consistent pharmaceutical claim positions while handling each response on its own record.
The one-to-one relationship between actions, examiners, and art units makes matter-specific deadline and prior-art tracking essential. There is no shared art-unit concentration identified in the profile to support broad consolidation of prosecution issues.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 3 (75%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FUBARA, BLESSING M | 1 | 62.2% | +34.1% |
| PRONZATI, GINA | 1 | 65.9% | +48.3% |
| CORDAS, EMILY ANN | 1 | 50.9% | +57.4% |
| CONNORS, ALEXANDRA F | 1 | 23.7% | +45.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18798138 | CONDITIONED MEDIUM FROM CELLS CULTURED UNDER HYPOXIC CONDITIONS AND USES THEREOF | PRONZATI, GINA | — |
| 17607842 | CONDITIONED MEDIUM AND METHODS OF USE THEREOF | CORDAS, EMILY ANN | — |
| 17393356 | COMPOSITIONS AND METHODS FOR REDUCING INFLAMMATION | CONNORS, ALEXANDRA F | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18947213 | TOPICAL COMPOSITION AND METHOD OF USE | FUBARA, BLESSING M | — |
| 18798138 | CONDITIONED MEDIUM FROM CELLS CULTURED UNDER HYPOXIC CONDITIONS AND USES THEREOF | PRONZATI, GINA | — |
| 17607842 | CONDITIONED MEDIUM AND METHODS OF USE THEREOF | CORDAS, EMILY ANN | — |
| 17393356 | COMPOSITIONS AND METHODS FOR REDUCING INFLAMMATION | CONNORS, ALEXANDRA F | — |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| 1633 | 1 |
| 1632 | 1 |
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18947213 | TOPICAL COMPOSITION AND METHOD OF USE | FUBARA, BLESSING M | 1613 | §102§103§112DP | Non-Final OA | — | Pending | Nov 14, 2024 |
| 18798138 | CONDITIONED MEDIUM FROM CELLS CULTURED UNDER HYPOXIC CONDITIONS AND USES THEREOF | PRONZATI, GINA | 1633 | §102§103§112 | Non-Final OA | — | Pending | Aug 08, 2024 |
| 17607842 | CONDITIONED MEDIUM AND METHODS OF USE THEREOF | CORDAS, EMILY ANN | 1632 | §102§103Other | Final Rejection | — | Pending | Oct 29, 2021 |
| 17393356 | COMPOSITIONS AND METHODS FOR REDUCING INFLAMMATION | CONNORS, ALEXANDRA F | 1634 | §103§112 | Final Rejection | — | Pending | Aug 03, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAllergan Sales, LLC has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Blessing M Fubara has the most, with 1 of Allergan Sales, LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
